Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Histone Methylation Mark Analyses Distinguish Carts Manufactured from Distinct Sources and Uncover Novel Transcription Factors Associated with In Vivo Function of Carts after Infusion into DLBCL Patients That Are Not Identified By RNA-Seq

Salvatore Fiorenza, Ye Zheng, Jay Sarthy, Alyssa Sheih, Erik L Kimble, Delaney Kirchmeier, Derek Janssens, Tinh-Doan Phi, Jordan Gauthier, Alexandre V Hirayama, Qian Wu, Raphael Gottardo, Stanley R. Riddell, David G Maloney, Steven Henikoff, Cameron J. Turtle

Blood (2023) 142 (Supplement 1): 3454.

https://doi.org/10.1182/blood-2023-188269

Published: 2023

Journal Articles

Phase 2 Study of CD19 CAR T Cells with a Fully Human Binder for Large B-Cell Lymphoma in Relapse or Progression after a Murine Binder-Bearing CD19 CAR T-Cell Therapy

Blood (2023) 142 (Supplement 1): 6860.

https://doi.org/10.1182/blood-2023-181273

Published: 2023

Journal Articles

Factors Associated with Prolonged CRS and Neurotoxicity after Treatment with Axicabtagene Ciloleucel

Aya Albittar, Jenna M Voutsinas, Andrew J Portuguese, Jennifer J. Huang, Emily C Liang, Qian Wu, Xinyi Fan, Alexandre V Hirayama, Erik L Kimble, Lorenzo Iovino, Christina Poh, Ajay K Gopal, Mazyar Shadman, Brian G Till, Filippo Milano, Aude G Chapuis, Ryan D Cassaday, David G Maloney, Jordan Gauthier

Blood (2023) 142 (Supplement 1): 2126.

https://doi.org/10.1182/blood-2023-180128

Published: 2023

Journal Articles

Machine Learning-Based Time-Series Clustering Identifies Archetypal Trajectories of Hematotoxicity after CAR T-Cell Therapy

Blood (2023) 142 (Supplement 1): 2143.

https://doi.org/10.1182/blood-2023-174106

Published: 2023

Journal Articles

Day +3/Day 0 Ferritin Ratio: A Simple Point-of-Care Index Predictive of Severe Immune Effector Cell-Associated Neurotoxicity Syndrome after CD19 CAR T-Cell Therapy

Blood (2023) 142 (Supplement 1): 3495.

https://doi.org/10.1182/blood-2023-182597

Published: 2023

Journal Articles

Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel: Efficacy and Toxicity in a Real-World Setting

Andrew J Portuguese, Aya Albittar, Emily C Liang, Jennifer J. Huang, Alexandre V Hirayama, Erik L Kimble, Lorenzo Iovino, Christina Poh, Ajay K Gopal, Mazyar Shadman, Brian G Till, Hans-Peter Kiem, Filippo Milano, Aude G Chapuis, Folashade Otegbeye, Ryan D Cassaday, David G Maloney, Jordan Gauthier

Blood (2023) 142 (Supplement 1): 2131.

https://doi.org/10.1182/blood-2023-172978

Published: 2023

Journal Articles

Phase 2 Study of Anakinra to Prevent CRS and Neurotoxicity after Treatment with Lisocabtagene Maraleucel: Planned Interim Analysis

Blood (2023) 142 (Supplement 1): 6848.

https://doi.org/10.1182/blood-2023-172695

Published: 2023

Journal Articles

Phase I/II Study to Evaluate the Safety, Feasibility, and Efficacy of FP-1201 (Intravenous Interferon-Beta-1a) to Prevent Toxicities after CD19-Directed CAR T-Cell Therapy: Trial in Progress

Emily C Liang, Erik L Kimble, Aya Albittar, Jennifer J. Huang, Andrew J Portuguese, Aiko Torkelson, Delaney Kirchmeier, Abigail Chutnik, Barbara Pender, Sylvain Simon, Tony Chour, Evan W. Newell, Rahul Banerjee, David G Maloney, Alexander Spicer, Juho Jalkanen, Alexandre V Hirayama, Jordan Gauthier

Blood (2023) 142 (Supplement 1): 4860.

https://doi.org/10.1182/blood-2023-173152

Published: 2023

Journal Articles

Predicted Fludarabine Exposure Is Independently Associated with CRS and ICANS after CD19 CAR T-Cell Therapy

Ivan J. Huang, Rosa Yeh, Karen Sweiss, Pritesh Patel, Alexandre Vinaud Hirayama, Erik L. Kimble, Krishna R. Juluri, Mazyar Shadman, Cameron J. Turtle, David G. Maloney, Jordan Gauthier

Blood (2022) 140 (Supplement 1): 12725–12727.

https://doi.org/10.1182/blood-2022-156751

Published: 2022

Journal Articles

CAR T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma Using a Fully Human CD19-Targeted Single Chain Variable Fragment: Results of a First-in-Human Phase I/II Study

Nicolas Gazeau, Salvatore Fiorenza, Erik L. Kimble, Alexandre Vinaud Hirayama, Barbara S. Pender, Henna A. Di, Delaney R. Kirchmeier, Brian G. Till, Mazyar Shadman, Stanley R. Riddell, David G. Maloney, Cameron J. Turtle, Jordan Gauthier

Blood (2022) 140 (Supplement 1): 10363–10365.

https://doi.org/10.1182/blood-2022-157826

Published: 2022

Journal Articles

Efficacy and Safety of CAR T-Cell Therapy Using a Fully Human CD19-Targeted Binder in Adults with Relapsed/Refractory B-ALL

Jordan Gauthier, Nicolas Gazeau, Salvatore Fiorenza, Erik L. Kimble, Alexandre Vinaud Hirayama, Barbara S. Pender, Henna N Di, Delaney R. Kirchmeier, Mazyar Shadman, Ryan D. Cassaday, Stanley R. Riddell, David G. Maloney, Cameron J. Turtle

Blood (2022) 140 (Supplement 1): 10360–10362.

https://doi.org/10.1182/blood-2022-156822

Published: 2022

Journal Articles

Timing of PD-L1 Blockade with Durvalumab May Affect Outcomes of CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma

Alexandre Vinaud Hirayama, Salvatore Fiorenza, Jordan Gauthier, Jenna M. Voutsinas, Qian Vicky Wu, Erik L. Kimble, Barbara S. Pender, Delaney R. Kirchmeier, Henna A. Di, Ryan D. Cassaday, Aude G. Chapuis, Damian J. Green, Hans-Peter Kiem, Filippo Milano, Mazyar Shadman, Brian G. Till, Stanley R. Riddell, David G. Maloney, Cameron J. Turtle

Blood (2022) 140 (Supplement 1): 7447–7449.

https://doi.org/10.1182/blood-2022-168185

Published: 2022

Journal Articles

Targeting the Membrane-Proximal C2-Set Domain of CD33 for Improved CD33-Directed CAR T Cell Therapy

Salvatore Fiorenza, George S. Laszlo, Tinh-Doan Phi, Margaret C. Lunn, Delaney R. Kirchmeier, Colin D. Godwin, Erik L. Kimble, Cameron J. Turtle, Roland B. Walter

Blood (2021) 138 (Supplement 1): 2776.

https://doi.org/10.1182/blood-2021-149642

Published: 2021

Journal Articles

Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies

Blood (2021) 137 (3): 323–335.

https://doi.org/10.1182/blood.2020006770

Published: 2021

Includes: Supplemental data

NARROW

Histone Methylation Mark Analyses Distinguish Carts Manufactured from Distinct Sources and Uncover Novel Transcription Factors Associated with In Vivo Function of Carts after Infusion into DLBCL Patients That Are Not Identified By RNA-Seq

Phase 2 Study of CD19 CAR T Cells with a Fully Human Binder for Large B-Cell Lymphoma in Relapse or Progression after a Murine Binder-Bearing CD19 CAR T-Cell Therapy

Factors Associated with Prolonged CRS and Neurotoxicity after Treatment with Axicabtagene Ciloleucel

Machine Learning-Based Time-Series Clustering Identifies Archetypal Trajectories of Hematotoxicity after CAR T-Cell Therapy

Day +3/Day 0 Ferritin Ratio: A Simple Point-of-Care Index Predictive of Severe Immune Effector Cell-Associated Neurotoxicity Syndrome after CD19 CAR T-Cell Therapy

Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel: Efficacy and Toxicity in a Real-World Setting

Phase 2 Study of Anakinra to Prevent CRS and Neurotoxicity after Treatment with Lisocabtagene Maraleucel: Planned Interim Analysis

Phase I/II Study to Evaluate the Safety, Feasibility, and Efficacy of FP-1201 (Intravenous Interferon-Beta-1a) to Prevent Toxicities after CD19-Directed CAR T-Cell Therapy: Trial in Progress

Predicted Fludarabine Exposure Is Independently Associated with CRS and ICANS after CD19 CAR T-Cell Therapy

CAR T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma Using a Fully Human CD19-Targeted Single Chain Variable Fragment: Results of a First-in-Human Phase I/II Study

Efficacy and Safety of CAR T-Cell Therapy Using a Fully Human CD19-Targeted Binder in Adults with Relapsed/Refractory B-ALL

Timing of PD-L1 Blockade with Durvalumab May Affect Outcomes of CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma

Targeting the Membrane-Proximal C2-Set Domain of CD33 for Improved CD33-Directed CAR T Cell Therapy

Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only